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Summary
The intracellular TRIM5a protein successfully inhibits
HIV-1 infection in rhesus monkeys, but not in humans
[1–6]. A few amino acids in the virus-interacting SPRY
domain [7] were found to be responsible for most of
this anti-viral specificity [8–10], raising the possibility
that genetic variation among humans could result in
TRIM5a proteins with a spectrum of potencies. We
found several nonsynonymous SNPs at the human
TRIM5 locus, but only one of these (H43Y) was found
to have a significant functional consequence. We dem-
onstrate that H43Y impairs TRIM5a restriction of two
distantly related retroviruses. H43Y lies in the RING
domain of TRIM5a and may negatively affect its puta-
tive E3 ubiquitin ligase activity. This detrimental allele
dates back to before the African diaspora and is found
at a frequency of 43% in indigenous Central and South
Americans. We suggest that relaxed constraint due to
a recent period of low retroviral challenge has allowed
the deleterious H43Y mutation to persist and even to
expand after the bottleneck that occurred upon human
migration to the New World. The unexpectedly high
frequency of an impaired retroviral restriction allele
among humans is likely to have a significant impact
on our ability to ward off future retroviral challenges.
Results and Discussion
To test the hypothesis that variation in the human gene
pool encodes TRIM5aproteins with a spectrum of antivi-
ral potencies, we surveyed global variation in the human
TRIM5a gene. We sequenced 4879 bp of genomic se-
quence, from 2 bp upstream of the start codon in exon
2 to the stop codon in exon 8 (a large intron of 10.5 kb
between exons 4 and 5 was not sequenced) from 37
geographically diverse, indigenous humans (74 chromo-
somes from Africa, the Middle East, Southeast Asia, Eu-
rope, and Central and South America, all selected from
the Coriell Human Variation collection of the NIGMS re-
pository). A total of 20 SNPs were identified (Figures 1A
and 1C), which ranged in frequency from 1% to 50% (Fig-
ure 1D). Sequence from one chimpanzee and one gorilla
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allele) and derived (black, minor allele) states for each
SNP (Figure 1A) and to determine changes that have
been fixed specifically in the human lineage in the last 5
million years (Figure 1B). Positive selection of TRIM5a
throughout primate evolution has been concentrated in
the SPRY domain [10, 11] and five replacement changes
in the SPRY domain have been fixed in the human lineage
since its common ancestor with chimpanzee (Figure 1B).
Because the SPRY domain encodes determinants of
capsid recognition [8–10, 12, 13], these changes may re-
flect newspecificities that were fixed during the last 5mil-
lion years of human evolution.
We also find nucleotide polymorphisms throughout
the length of the gene, including six nonsynonymous
SNPs (nsSNPs). Bioinformatic analyses predict that
three of these, H43Y, V112F, and R238W, could poten-
tially affect the function of the TRIM5a protein (see the
Supplemental Data available with this article online).
To explore this possibility, we assayed each of the six
nsSNPs for any effect on TRIM5a function in CRFK cells
(feline renal fibroblasts), which have been used to test
the activity of exogenously expressed primate proteins
against retroviruses because they themselves have no
intrinsic retroviral restriction [3]. CRFK cells were stably
transduced with human TRIM5a or variants carrying
each individual derived nsSNP. These cell lines, expres-
sing roughly equal levels of each TRIM5a variant (Fig-
ure 2A), were challenged with HIV-1 expressing GFP
and assayed for percent infection. As has been previ-
ously reported [1], ‘‘wild-type’’ human TRIM5a has only
a moderate ability to restrict HIV-1 replication in this
assay (Figure 2B). Whereas V112F, R136Q, R238W,
G249D, and H419Y had no significant effect on TRIM5a
restriction, we found that H43Y significantly reduced vi-
ral restriction to a level similar to that of CRFK cells ex-
pressing no exogenous TRIM5a.
Positive selection of the TRIM5a gene predates pri-
mate lentiviruses like HIV-1 by many millions of years
[10] and was likely driven by interactions with older
endogenous and exogenous retroviruses. Moreover, be-
cause HIV-1 was only recently introduced into the hu-
man population [14], standing genetic variation in human
TRIM5a is unlikely to have been shaped by HIV-1. In con-
trast to their restriction of HIV-1, human cells have been
found to efficiently restrict N-MLV [15], a murine gretro-
virus that is more closely related to the endogenous ret-
roviruses that have been active during primate evolution
[16]. Human TRIM5a has been shown to be necessary
and sufficient for the N-MLV restriction [2–5]. Thus, re-
striction against N-MLV is likely to be a more evolution-
arily relevant activity for TRIM5a. When we tested the
various nsSNPs for N-MLV restriction, we found that
V112F, R136Q, R238W, G249D, and H419Y did not affect
TRIM5a restriction, but H43Y was again seriously com-
promised (Figure 2C). H43Y was found to have no effect
on the related B-MLV (Figure 2D), another MLV variant
that is resistant to TRIM5a restriction [2–5, 15].
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96Figure 1. Polymorphism and Divergence in
the Human TRIM5a Gene
(A) The grid illustrates derived and ancestral
states at SNP sites in the 37 humans sam-
pled. Each row represents one human, and
each column represents a SNP site (with
base coordinates beginning at 1 = ‘‘A’’ of
the ATG translational start site). White boxes
indicate homozygous for the ancestral state
(as defined by the major human allele and
the chimpanzee sequence at the bottom),
black boxes indicate homozygous for the de-
rived state, and split boxes indicate heterozy-
gosity. SNPs in exons are indicated along the
top by their amino acid coordinates. We also
obtained the sequence of one gorilla (bot-
tom), which shares the human polymorphism
at the 22 position and has a unique base at
777. The unsequenced intron falls between
sites 1942 and 12468 and is indicated by
a break in the grid.
(B and C) A schematic illustrates the TRIM5a
genomic structure with coding exons indi-
cated by black boxes. The twenty SNPs that
were identified are shown spatially on the
gene diagram (C). The chimpanzee and go-
rilla sequences were used to define fixed hu-
man-specific changes (B). In both diagrams,
flags indicate replacement changes, whereas
stems indicate synonymous changes.
(D) The frequency of each SNP is plotted di-
rectly below its position in the schematic in
(C) (light bars are silent SNPs, dark bars are
nsSNPs).To assay whether the impaired retroviral restriction
seen with exogenously expressed TRIM5a-H43Y trans-
lates to altered susceptibility in human cells, we tested
B-lymphocytes from four individuals of our South Amer-
ican population set: one homozygous for H43 (‘‘wild-
type’’), two homozygous for H43Y, and one heterozygous
at this site. We infected these cell lines with N-MLV,
B-MLV, or HIV-1. Human cells are profoundly resistant
to infection by N-MLV due to endogenously expressed
TRIM5a [15]; correspondingly, B-lymphocytes homozy-
gous for ‘‘wild-type’’ TRIM5a were very poorly infected
by N-MLV (Figure 3A). However, we found that cells
from individuals homozygous for the H43Y mutation
could be infected with N-MLV about 100-fold more effi-
ciently whereas B-lymphocytes from heterozygous indi-
viduals had an intermediate phenotype (we confirmed
that the heterozygote cell line transcribes both TRIM5a
alleles). Therefore, there was a direct correlation be-
tween the TRIM5a genotype and the ability of humancells to restrict this gretrovirus. Although these cell lines
likely differ at many other genetic loci, two lines of evi-
dence suggest that the TRIM5 locus is responsible for
the decreased restriction of N-MLV. First, TRIM5a has
been previously shown to be the major human determi-
nant of N-MLV restriction [2-5]. Second, we find that
there is less than a 2-fold difference between the cell
lines in their ability to be infected by B-MLV (Figure 3B),
a variant of MLV that differs from N-MLV by a single
amino acid change in its capsid that renders it immune
to TRIM5a restriction [2–5, 15]. These results and their
congruence with what we observed by expressing ex-
ogenous TRIM5a alleles in CRFK cells (Figure 2) demon-
strate that genetic variation in the TRIM5 locus has re-
sulted in a loss of retroviral restriction in the human
population. We also challenged the B-lymphocyte cells
with HIV-1 and found that there was no significant effect
of the H43Y change (Figure 3C). This is not surprising
because previous studies have shown that although
An Impaired Human Allele of the Anti-Viral TRIM5a
97Figure 2. H43Y Negatively Impacts the Po-
tency of Human TRIM5a against Retroviruses
(A) A retroviral expression vector encoding
human TRIM5a was altered to contain each
of the six nsSNPs. These vectors were used
to stably transduce feline fibroblasts (CRFK
cells), which have no intrinsic restriction to
retroviruses. A Western blot shows that the
HA-tagged TRIM5a variants are expressed
at equal levels. A blot with actin antibody
serves as a loading control. (Based on the
actin probe, H43Y may be slightly overex-
pressed compared to wild-type, which means
that the detrimental effects of this allele are
even slightly underestimated.) Because none
of our human samples contained R238W in
the absence of R136Q (see Figure 1A), we
also tested this double mutant. Its phenotype
is indistinguishable from R238W in every
functional assay (data not shown).
(B–D) CFRK cells (closed blue circle) or
those expressing human TRIM5a variants (all
other symbols) were challenged with GFP-
expressing HIV-1 (B), N-MLV (C), or B-MLV
(D). H43Y (open green circle) is the only nsSNP
that causes a significant change in pheno-
type, losing restriction to HIV-1 and N-MLV
compared to wild-type human TRIM5a (closed
pink square). As expected, neither wild-type
TRIM5a nor the H43Y variant has the ability
to restrict B-MLV.human TRIM5a has weak activity against HIV-1 when it
is expressed exogenously, its endogenous expression
is not a major factor in restriction of HIV-1 in human cells
[17, 18].
The H43Y polymorphism changes an amino acid in the
‘‘loop 2’’ region of the TRIM5a RING domain (Figure 3D),
altering a position where histidine has been strictly con-
served throughout primate evolution [10] (Supplemental
Data). A shorter isoform of TRIM5 has been shown to
have E3 ubiquitin ligase activity [19], and it has beenproposed that TRIM5a might neutralize retroviruses
through a ubiquitin-mediated pathway requiring the
RING motif. This loop 2 region of a similar RING domain
from human c-cbl has been previously implicated as the
interaction interface between E2 and E3 enzymes [20].
If E2-E3 interaction were perturbed by the H43Y muta-
tion, this would be consistent with the general (versus
virus-specific) impairment of retroviral restriction that
we have observed. Mutations of the invariant cysteine
residues that coordinate zinc in the RING domain also
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(A-C) B cells from four Brazilian individuals were used to test restriction of MLV and HIV in the context of human cells with different genotypes at
H43. The wild-type TRIM5a homozygote (H43/H43, white) is very efficient at restricting N-MLV, whereas the H43Y heterozygote (H43/H43Y, gray)
and homozygotes (H43Y/H43Y, black) are progressively worse at restricting N-MLV. All genotypes are essentially equal in their restriction of
B-MLV and HIV-1. Two different H43Y/H43Y cell lines show consistent results. This is a representative experiment, which was performed three
separate times.
(D) A schematic of the TRIM5a protein, with the location of the six nonsynonymous SNPs identified in our study.significantly impair, but like H43Y, do not completely
abolish restriction activity [1, 21]. We cannot formally
rule out the possibility that H43Y is functionally superior
at restricting a class of viruses other than that for which
the wild-type variant is optimized. However, the fact that
we have detected impaired function of H43Y against two
distantly related retroviruses, as well as its location in
the RING loop2, suggest a global loss of function.
Why has a detrimental TRIM5a allele persisted in the
human population? We first consider H43Y prevalence
in the Old World (Africa/Asia/Europe). H43Y is present
on 4% of the chromosomes we sampled from the Old
World (2 out of 46 chromosomes, Figure 1A). In this set,
we did not observe H43Y in any of the African samples,
but we did find a low incidence when we assayed addi-
tional samples representing Africans from either north
or south of the Sahara (H43Y on 2 of 10 and 0 of 16 chro-
mosomes, respectively) from the Coriell human variation
panel. Consistent with H43Y origination in Africa, we
estimated that the H43Y haplotype is 500,000 years old
(see Supplemental Data). This compares to an estimate
of 600,000 years for average, neutral human polymor-
phisms [22], suggesting that H43Y is not remarkable in
terms of its age. We consider three models for the global
persistence of H43Y in human populations: balancing
selection, genetic drift, and positive selection.
First, we considered that H43Y might persist as a
balanced polymorphism. Balancing selection of H43Y
would carry the signature of linked, medium to high-
frequency polymorphisms in the 50 region of the gene.
To look for such a signature, we calculated the Tajima’s
D statistic, which summarizes the allele frequency distri-
bution. For the 50 half of the gene (exons 2 to 4), which
includes H43Y, we found Tajima’s D to be +0.631, con-
sistent with a trend toward medium to high-frequency
SNPs, but not statistically significant for rejection of
neutrality. In contrast, in the SPRY domain, Tajima’s
D = 20.901, in which the negative value indicates
a skew toward rare alleles consistent with a recentselective sweep in the human population, although this
single polymorphism was also not sufficient for a statis-
tically significant rejection of neutrality. However, we
used the Hudson-Kreitman-Aguade (HKA) test to con-
firm that the polymorphism pattern of the 50 half of the
gene (exons 2–4) is significantly discordant from that
of the SPRY domain (p = 0.02). Thus, although we do
not find statistical support while individually testing for
either a selective sweep in the SPRY domain or bal-
anced polymorphisms in the 50 region, these results sug-
gest that natural selection has influenced one or both
these regions during human evolution, with the most
likely scenario being a selective sweep of the SPRY do-
main where there has been strong positive selection
throughout primate evolution [10, 11]. Indeed, we find
only one polymorphism, at low frequency, in the last
1.5 kb spanning exons six through eight (exon 8 en-
codes the SPRY domain). However, we do not find
strong evidence for balancing selection acting on H43Y.
A second possibility for H43Y’s persistence is a recent
global relaxation of selective constraints on retroviral
defense genes, resulting in this impaired allele having
no contemporary fitness cost. We have previously sug-
gested that endogenous retroviruses (ERVs) are a likely
cause for the positive selection of TRIM5a in primates
[10]. The human genome has had remarkable success
in eliminating these genomic pathogens; the published
human genome sequence contains thousands of ERV
sequences, all of which are defective [23]. Only the
HERV-K family appears to have been recently active in
the human lineage [24, 25]. Furthermore, humans may
have faced fewer challenges from exogenous retrovi-
ruses, as we are currently infected by only HIV and
HTLV, with HIV having entered the human population
only within the last century [14, 26]. Together, dimin-
ished pressure from endogenous and exogenous retro-
viruses in recent evolutionary history may have allowed
the propagation of an impaired allele of TRIM5 and per-
haps other retroviral defense genes.
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paired retroviral defense genes could actually have a fit-
ness advantage. Under this model, pathogen defense
genes themselves pose a selective cost to the host.
For example, the RPM1 gene from Arabidopsis thaliana
confers resistance against Pseudomonas infection, yet
field experiments reveal a large fitness cost imposed
by RPM1 in the absence of Pseudomonas [27]. In the
case of TRIM5a, a fitness cost in the absence of retrovi-
ruses might result from deleterious turnover of host
proteins by this cytoplasmically active ubiquitin ligase,
especially because TRIM5a appears to be changing tar-
get specificity at a rapid evolutionary rate [10, 11]. Thus,
evolutionary periods in which hosts go unchallenged by
parasites can lead to the persistence or even expansion
of impaired defense alleles.
Amazingly, H43Y is found at a frequency of 43% in our
Central and South American samples (12/28 chromo-
somes), despite being detrimental to TRIM5a function.
This high frequency could be traced to the population
bottleneck that occurred when humans migrated to the
Americas with a very small effective population size, ap-
proximately 15,000 to 30,000 years ago [28]. Under this
demographic model, the founder populations could
have had a high frequency of H43Y and selective pres-
sures against this allele were not stringent enough to re-
duce its frequency in ensuing generations.
Our study thus reveals that a significant fraction of the
human population harbors an impaired variant of an im-
portant retroviral defense gene. Regardless of the selec-
tive or demographic constraints that are responsible for
the current high frequency of H43Y, there may be pro-
found future health implications of a detrimental retrovi-
ral restriction allele segregating at high frequency in the
human population. Moreover, this analysis illustrates
how human evolutionary history can shape our suscep-
tibility to present-day and future viral infections.
Supplemental Data
Supplemental Data include Experimental Procedures, two figures,
and one table and are available with this article online at http://
www.current-biology.com/cgi/content/full/16/1/95/DC1/.
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